HOME    SEARCH    ABOUT US    CONTACT US    HELP   
           
Rule: 37.57.301 Prev     Up     Next    
Rule Title: DEFINITIONS
Add to My Favorites
Add to Favorites
Department: PUBLIC HEALTH AND HUMAN SERVICES
Chapter: MATERNAL AND CHILD HEALTH
Subchapter: Infant Screening Tests and Eye Treatment
 
Latest version of the adopted rule presented in Administrative Rules of Montana (ARM):

Printer Friendly Version

37.57.301    DEFINITIONS

As used in this subchapter, the following definitions apply:

(1) "Health care facility" means a hospital or other facility licensed by or located in the state of Montana for the purpose of providing health care services, and which provides primary health care services for newborns at birth.

(2) "Newborn" means an infant in the first 28 days of life.

(3) "Newborn screening tests" are screening tests, procedures, or both for the following conditions:

(a) Acylcarnitine Disorders:

(i) Fatty Acid Oxidation Disorders:

(A) Carnitine uptake defect;

(B) Long-chain L-3-OH acyl-CoA dehydrogenase deficiency;

(C) Medium-chain acyl-CoA dehydrogenase deficiency;

(D) Trifunctional protein deficiency; and

(E) Very long-chain acyl-CoA dehydrogenase deficiency;

(ii) Organic Acidemia Disorders:

(A) 3-hydroxy-3-methylglutaryl-CoA lyase deficiency;

(B) 3-Methylcrotonyl-CoA carboxylase deficiency;

(C) β-ketothiolase deficiency;

(D) Glutaric acidemia type I;

(E) Isovaleric acidemia;

(F) Methylmalonic acidemia (Cbl A,B);

(G) Methylmalonic acidemia (mutase deficiency);

(H) Multiple carboxylase deficiency; and

(I) Propionic acidemia;

(b) Amino Acid Disorders:

(i) Argininosuccinic acidemia;

(ii) Citrullinemia type 1;

(iii) Homocystinuria;

(iv) Maple syrup urine disease;

(v) Classic Phenylketonuria; and

(vi) Tyrosinemia type I;

(c) Biotinidase deficiency;

(d) Classical galactosemia;

(e) Congenital adrenal hyperplasia;

(f) Primary congenital hypothyroidism;

(g) Cystic fibrosis;

(h) Hemoglobinopathies, including:

(i) Hb S/β -thalassemia;

(ii) Hb SC disease; and

(iii) Hb SS disease; and

(i) Critical congenital heart disease, including:

(i) hypoplastic left heart syndrome;

(ii) pulmonary atresia;

(iii) tetralogy of Fallot;

(iv) total anomalous pulmonary venous return;

(v) transposition of the great arteries;

(vi) tricuspid atresia;

(vii) truncus arteriosus; and

(j) Severe combined immunodeficiency disease.

History: 50-19-202, MCA; IMP, 50-19-203, MCA; Eff. 12/31/72; AMD, Eff. 5/6/74; AMD, 1985 MAR p. 1612, Eff. 11/1/85; TRANS, from DHES, 2001 MAR p. 398; AMD, 2003 MAR p. 1298, Eff. 7/1/03; AMD, 2008 MAR p. 44, Eff. 1/18/08; AMD, 2014 MAR p. 1411, Eff. 7/1/14; AMD, 2015 MAR p. 828, Eff. 7/1/15.


 

 
MAR Notices Effective From Effective To History Notes
37-711 7/1/2015 Current History: 50-19-202, MCA; IMP, 50-19-203, MCA; Eff. 12/31/72; AMD, Eff. 5/6/74; AMD, 1985 MAR p. 1612, Eff. 11/1/85; TRANS, from DHES, 2001 MAR p. 398; AMD, 2003 MAR p. 1298, Eff. 7/1/03; AMD, 2008 MAR p. 44, Eff. 1/18/08; AMD, 2014 MAR p. 1411, Eff. 7/1/14; AMD, 2015 MAR p. 828, Eff. 7/1/15.
37-677 7/1/2014 7/1/2015 History: 50-19-202, MCA; IMP, 50-19-203, MCA; Eff. 12/31/72; AMD, Eff. 5/6/74; AMD, 1985 MAR p. 1612, Eff. 11/1/85; TRANS, from DHES, 2001 MAR p. 398; AMD, 2003 MAR p. 1298, Eff. 7/1/03; AMD, 2008 MAR p. 44, Eff. 1/18/08; AMD, 2014 MAR p. 1411, Eff. 7/1/14.
37-422 1/18/2008 7/1/2014 History: 50-19-202, MCA; IMP, 50-19-203, MCA; Eff. 12/31/72; AMD, Eff. 5/6/74; AMD, 1985 MAR p. 1612, Eff. 11/1/85; TRANS, from DHES, 2001 MAR p. 398; AMD, 2003 MAR p. 1298, Eff. 7/1/03; AMD, 2008 MAR p. 44, Eff. 1/18/08.
7/1/2003 1/18/2008 History: Sec. 50-19-202, MCA; IMP, Sec. 50-19-203, MCA; Eff. 12/31/72; AMD, Eff. 5/6/74; AMD, 1985 MAR p. 1612, Eff. 11/1/85; TRANS, from DHES, 2001 MAR p. 398; AMD, 2003 MAR p. 1298, Eff. 7/1/03.
Home  |   Search  |   About Us  |   Contact Us  |   Help  |   Disclaimer  |   Privacy & Security